CN101166733A - 作为磷酸二酯酶4抑制剂的吡唑衍生物 - Google Patents

作为磷酸二酯酶4抑制剂的吡唑衍生物 Download PDF

Info

Publication number
CN101166733A
CN101166733A CNA2005800431961A CN200580043196A CN101166733A CN 101166733 A CN101166733 A CN 101166733A CN A2005800431961 A CNA2005800431961 A CN A2005800431961A CN 200580043196 A CN200580043196 A CN 200580043196A CN 101166733 A CN101166733 A CN 101166733A
Authority
CN
China
Prior art keywords
phenyl
ethyl
pyrazol
alkyl
indazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800431961A
Other languages
English (en)
Chinese (zh)
Inventor
A·霍珀
R·F·邓恩
E·M·屈斯特
R·D·孔蒂切洛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memory Pharmaceuticals Corp
Original Assignee
Memory Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memory Pharmaceuticals Corp filed Critical Memory Pharmaceuticals Corp
Publication of CN101166733A publication Critical patent/CN101166733A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNA2005800431961A 2004-10-15 2005-10-14 作为磷酸二酯酶4抑制剂的吡唑衍生物 Pending CN101166733A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61872504P 2004-10-15 2004-10-15
US60/618,725 2004-10-15

Publications (1)

Publication Number Publication Date
CN101166733A true CN101166733A (zh) 2008-04-23

Family

ID=35759321

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800431961A Pending CN101166733A (zh) 2004-10-15 2005-10-14 作为磷酸二酯酶4抑制剂的吡唑衍生物

Country Status (7)

Country Link
US (2) US7432266B2 (enExample)
EP (1) EP1799673A1 (enExample)
JP (1) JP2008516964A (enExample)
CN (1) CN101166733A (enExample)
AU (1) AU2005295753A1 (enExample)
CA (1) CA2584317A1 (enExample)
WO (1) WO2006044528A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104230890A (zh) * 2013-06-19 2014-12-24 信诺凯（北京）化工有限公司 吡啶-2-胺衍生物及其制法和药物组合物与用途
WO2015161830A1 (en) * 2014-04-25 2015-10-29 Sunshine Lake Pharma Co., Ltd. Heteroaromatic derivatives and pharmaceutical applications thereof
CN106188027A (zh) * 2015-09-02 2016-12-07 广东东阳光药业有限公司 芳杂环类衍生物及其在药物中的应用

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ564916A (en) * 2005-06-27 2011-03-31 Exelixis Inc Imidazole based LXR modulators
US20070254913A1 (en) * 2006-04-19 2007-11-01 Dunn Robert F Phosphodiesterase 4 inhibitors
CA2661992A1 (en) * 2006-09-06 2008-03-13 Kyorin Pharmaceutical Co., Ltd. Pyrazolopyridine derivative and phosphodiesterase (pde) inhibitor containing the same as active ingredient
CA2671543A1 (en) * 2006-12-05 2008-06-12 Chung-Ming Sun Indazole compounds
KR20090094125A (ko) 2006-12-08 2009-09-03 엑셀리시스, 인코포레이티드 Ｌｘｒ 및 ｆｘｒ 조절자
FR2916758B1 (fr) * 2007-06-04 2009-10-09 Sanofi Aventis Sa Derives de 1-benzylpyrazole, leur preparation et leur application en therapeutique
AU2008276451A1 (en) * 2007-07-17 2009-01-22 Zalicus Inc. Treatments of B-cell proliferative disorders
CA2694987A1 (en) * 2007-07-17 2009-01-22 Combinatorx, Incorporated Combinations for the treatment of b-cell proliferative disorders
US20100009934A1 (en) * 2008-06-09 2010-01-14 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
EP2951161A1 (en) 2013-02-04 2015-12-09 Grünenthal GmbH 4-amino substituted condensed pyrimidine compounds as pde4 inhibitors
US10357486B2 (en) 2013-08-16 2019-07-23 Universiteit Maastricht Treatment of cognitive impairment with PDE4 inhibitor
WO2017012576A1 (en) * 2015-07-23 2017-01-26 Glaxosmithkline Intellectual Property Development Limited Compounds
EA033978B1 (ru) * 2015-09-11 2019-12-16 Бёрингер Ингельхайм Интернациональ Гмбх Пиразолилзамещенные гетероарилы и их применение в качестве лекарственных средств
JP2023542789A (ja) * 2020-09-28 2023-10-12 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド ピラゾール化合物並びにその調製方法及び使用
WO2025201504A1 (en) * 2024-03-29 2025-10-02 Beigene (Suzhou) Co., Ltd. Kat6 inhibitors

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
DE2413935A1 (de) 1974-03-20 1975-10-16 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone
DE2834114A1 (de) 1978-08-01 1980-02-14 Schering Ag Polyalkoxyphenylpyrrolidone iii, verfahren zu ihrer herstellung und ihre verwendung
DD295358A5 (de) 1989-06-28 1991-10-31 �����@������������������k�� Verfahren zur racemattrennung von 4-aryl-2-oxo-pyrrolidin-3-carbonsaeure-estern
US5935978A (en) 1991-01-28 1999-08-10 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
PT100441A (pt) 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
AU2869092A (en) 1991-10-11 1993-05-03 Smithkline Beecham Corporation Heterocyclic 3-phenylpyrrolidin-2-ones, their preparation and use for the manufacture of a medicament for inhibiting tumor necrosis factor production
DK0607373T3 (da) 1992-06-15 1997-10-13 Celltech Therapeutics Ltd Trisubstituerede phenylderivater som selektive phosphodiesterase IV-inhibitorer.
US5814651A (en) 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
TW263495B (enExample) 1992-12-23 1995-11-21 Celltech Ltd
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
WO1995026325A2 (en) 1994-03-25 1995-10-05 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
AU699085B2 (en) 1994-04-21 1998-11-19 Schering Aktiengesellschaft PDE IV inhibitors for treating Multiple Sclerosis
GB9412383D0 (en) 1994-06-21 1994-08-10 Celltech Ltd Chemical compound
DE19518082A1 (de) * 1995-05-17 1996-11-21 Merck Patent Gmbh 4(-Arylaminomethylen)-2,4-dihydropyrazol-3-one
AU7257096A (en) * 1995-10-04 1997-04-28 Fmc Corporation Herbicidal 6-heterocyclic indazole derivatives
DE19601938A1 (de) 1996-01-12 1997-07-17 Schering Ag Neue Phosphodiesteraseinhibitoren
JP3152940B2 (ja) * 1996-06-25 2001-04-03 ファイザー インク． ホスホジエステラーゼ（ｐｄｅ）ｉｖ型および腫瘍壊死因子（ｔｎｆ）阻害物質としての置換インダゾール誘導体及びその使用法
JPH1072415A (ja) 1996-06-26 1998-03-17 Nikken Chem Co Ltd ３−アニリノ−２−シクロアルケノン誘導体
GB9622386D0 (en) 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
WO1998058901A1 (en) 1997-06-24 1998-12-30 Nikken Chemicals Co., Ltd. 3-anilino-2-cycloalkenone derivates
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
BR9813938A (pt) * 1997-11-04 2000-09-26 Pfizer Prod Inc Compostos terapeuticamente ativos baseados na substituição bioisóstera de indazol por catecol em inibidores de pde4
AU4308300A (en) 1999-05-03 2000-11-17 Dr. Reddy's Research Foundation Pyrazoles having antiinflammatory activity
JP2001039954A (ja) * 1999-05-24 2001-02-13 Tomono Agrica Co Ltd ヘテロ環誘導体
CA2392931A1 (en) 1999-12-03 2001-06-07 Pfizer Products Inc. Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents
US6258833B1 (en) 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6372777B1 (en) 1999-12-23 2002-04-16 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
GB0003257D0 (en) * 2000-02-11 2000-04-05 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
AU4215801A (en) 2000-03-16 2001-09-24 Inflazyme Pharm Ltd Benzylated pde4 inhibitors
EP1276736A2 (en) * 2000-04-25 2003-01-22 Pharmacia Corporation Regioselective synthesis of 3,4-di(carbocyclyl or heterocyclyl)thiophenes
AU2002241596A1 (en) 2000-11-02 2002-06-18 Research Foundation Of City University Of New York Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4
US6495154B1 (en) 2000-11-21 2002-12-17 Vivus Inc. On demand administration of clomipramine and salts thereof to treat premature ejaculation
US6673818B2 (en) 2001-04-20 2004-01-06 Pharmacia Corporation Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
WO2002088107A1 (fr) * 2001-04-26 2002-11-07 Eisai Co., Ltd. Compose azote a anneaux condenses possedant un groupe pyrazolyle et servant de substituant, et composition medicale le comprenant
US20030162824A1 (en) * 2001-11-12 2003-08-28 Krul Elaine S. Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor
DE60326069D1 (de) * 2002-04-05 2009-03-19 Cadila Healthcare Ltd 4-(heterocyclyl)-benzenesulfoximin verbindungen zur behandlung entzündlicher erkrankungenen
UA79804C2 (en) * 2002-07-03 2007-07-25 Janssen Pharmaceutica Nv Cck-1 receptor modulators
WO2004033432A1 (ja) * 2002-10-09 2004-04-22 Ssp Co., Ltd. 抗真菌活性を有する新規ピラゾール化合物
WO2004094411A1 (en) * 2003-04-18 2004-11-04 Memory Pharmaceuticals Corporation Pyrazole derivatives as phosphodiesterase 4 inhibitors
HUP0304101A3 (en) * 2003-12-22 2008-10-28 Sanofi Aventis Pyrazole derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
US20070254913A1 (en) * 2006-04-19 2007-11-01 Dunn Robert F Phosphodiesterase 4 inhibitors

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104230890A (zh) * 2013-06-19 2014-12-24 信诺凯（北京）化工有限公司 吡啶-2-胺衍生物及其制法和药物组合物与用途
WO2015161830A1 (en) * 2014-04-25 2015-10-29 Sunshine Lake Pharma Co., Ltd. Heteroaromatic derivatives and pharmaceutical applications thereof
CN106188027A (zh) * 2015-09-02 2016-12-07 广东东阳光药业有限公司 芳杂环类衍生物及其在药物中的应用
CN106188027B (zh) * 2015-09-02 2020-10-20 广东东阳光药业有限公司 芳杂环类衍生物及其在药物中的应用

Also Published As

Publication number Publication date
CA2584317A1 (en) 2006-04-27
JP2008516964A (ja) 2008-05-22
AU2005295753A1 (en) 2006-04-27
US7723348B2 (en) 2010-05-25
WO2006044528A1 (en) 2006-04-27
US7432266B2 (en) 2008-10-07
US20060154960A1 (en) 2006-07-13
EP1799673A1 (en) 2007-06-27
US20080207660A1 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
US7723348B2 (en) Phosphodiesterase 4 inhibitors
CN1809559B (zh) 作为磷酸二酯酶4抑制剂的吡唑衍生物
US20070254913A1 (en) Phosphodiesterase 4 inhibitors
AU777701B2 (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
JP4928949B2 (ja) タンパク質キナーゼモジュレーターとしてのピラゾール誘導体
US7211594B2 (en) Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
KR101593253B1 (ko) 페닐 및 벤조디옥시닐 치환 인다졸 유도체
EP2097384B1 (en) Indozalyl sulphonamide derivatives useful as glucocorticoid modulators
CA2415492A1 (en) Pyrazole derivatives
CN102164917A (zh) 选择性调节cb2受体的磺酰基化合物
HRP20030783A2 (en) Pyrazole derivatives for treating hiv
JP2009512687A (ja) 炎症性疾患の処置におけるグルココルチコイド受容体モジュレーターとして使用するための新規二環式スルホンアミド類
CN100381425C (zh) 作为磷酸二酯酶4抑制剂的6-氨基-1h-吲唑及其药物组合物和用途
EP3986885B1 (en) Substituted pyrrolidine amides iv
HK1114616A (en) Pyrazole derivatives as phosphodiesterase 4 inhibitors
US10689354B2 (en) Aminoazole derivative
WO2002092593A1 (fr) Derives de 4-(4-pyridazinyl)pyrazole
EP4178954B1 (en) Substituted pyrrolidine amines and amides as mediator of the glucocortoid receptor
HK1081194B (en) 6-amino-1h-indazole compounds as phosphodiesterase 4 inhibitors, pharmaceutical compositions comprising the same, and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1114616

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20080423

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1114616

Country of ref document: HK